hodgkin's%20lymphoma
HODGKIN'S LYMPHOMA

Hodgkin's lymphoma is a malignancy that arises from germinal center B cell.

Histologically, there is a presence of multinucleated giant cells in a mixed inflammatory background.

It is also known as Hodgkin's disease, Hodgkin lymphoma or Hodgkin disease.

It commonly affects individuals ages 15-30 years old and those 55 years old and above.

The key morphologic characteristics include presence of Reed-Sternberg cells and lymphocyte-predominant cells.

Principles of Therapy

  • Management is based on the histological classification, anatomical stage, & prognosis of the disease
  • Treatment should be started as soon as diagnosis has been established to prevent further disease progression

Pharmacotherapy

Standard Chemotherapeutic Regimens

  • ABVD (Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine) 
    • Considered the gold standard for the treatment of limited & advanced Hodgkin's lymphoma
    • Developed as an alternative to Mechlorethamine, Vincristine, Procarbazine, & Prednisone (MOPP) regimen; with lesser adverse events
  • BEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone) 
    • Developed by the German Hodgkin’s Lymphoma Study Groups (GHSG) as an alternative to Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) therapy, but was associated with more acute toxicities
    • Escalated doses provide lower disease progression rates as compared to the standard dose, & is therefore preferred
    • Doses are increased by increasing the dosage per cycle or by decreasing the intervals per cycle or per drug administration
  • CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) 
    • Variant of Mechlorethamine, Vincristine, Procarbazine, & Prednisone (MOPP), replacing Mechlorethamine to avoid its toxic effects (severe nausea/vomiting, bone marrow depression)
  • CVP (Cyclophosphamide, Vincristine, Prednisone) 
    • Another hybrid of Mechlorethamine, Vincristine, Procarbazine, & Prednisone (MOPP) with reduced risk for infertility, secondary neoplasms, cardiac/lung toxicities used for patients with early stage or advanced disease
  • MOPP (Mechlorethamine, Vincristine, Procarbazine, & Prednisone) 
    • The 1st combination therapy used for advanced-stage Hodgkin's lymphoma but use was eventually discouraged due to side effects (eg sterility, leukemia)
    • Standard combination from which other chemotherapeutic combinations were derived
    • Clinical response was reported at 80%, with cure rate of 50% in advanced-stage patients
  • Stanford V (Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone) 
    • Uses a short but intensive treatment course combined with radiation therapy, providing good outcomes with less toxicities
    • Some studies have shown that the efficacy of Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) on overall response rate, overall survival, & 5-yr PFS is comparable to Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD)

Recommended Treatment Regimens

Favorable Stage IA/IIA Classic Hodgkin's Lymphoma (CHL)

  • Lower relapse rates & better results were seen with combined-modality therapies than in radiation therapy alone
  • Initial treatment with 2 cycles  Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) is recommended for patients with no bulky disease, <3 disease sites, erythrocyte sedimentation rate (ESR) <50 & no E-lesions, followed by restaging with positron emission tomography (PET)
    • Patients with Deauville scores of 1-4 may subsequently be given a dose of involved-site radiation therapy (ISRT)
    • Involved-site radiation therapy (ISRT) is recommended for biopsy-negative Deauville 5 patients
  • Patients with no bulky disease, <4 disease sites, ESR <50 & with or without E-lesions may be given either 2 or 3 cycles of ABVD, or Stanford V, followed by restaging with positron emission tomography (PET)
    • Patients previously given 3 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) is further restaged with the following treatment recommendations:
      • Deauville 1-2: observation or 1 cycle of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD); Deauvillle 3-4: 1 cycle of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) with involved-site radiation therapy (ISRT)
      • Deauville 5: biopsy is recommended, & 1 cycle of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) with involved-site radiation therapy (ISRT) if negative
    • Patients previously given 2 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) is further restaged with the following treatment recommendations:
      • Patients with Deauville 1-2 may be given 2 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) plus involved-site radiation therapy (ISRT); Deauvillle 3-4 may be given 2 cycles of dose-escalated BEACOPP with involved-site radiation therapy (ISRT) or 2 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) with involved-site radiation therapy (ISRT)
      • For patients with Deauville 5, biopsy is recommended, & 2 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) with involved-site radiation therapy (ISRT) if negative
    • Involved-site radiation therapy (ISRT) is recommended for Deauville 1-4 & biopsy-negative Deauville 5 patients previously given Stanford V
  • Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) is an alternative to Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) for the management of early-stage Hodgkin's lymphoma, with lesser chemotherapy-related adverse events such as infertility, cardiac toxicities, pulmonary diseases & growth of new tumors

Unfavorable Stage I/II Classic Hodgkin's Lymphoma (CHL)

  • Combined-modality therapy is preferred
  • Initial treatment with 4 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) is recommended, followed by restaging with positron emission tomography (PET) scan
    • Patients with Deauville scores of 1-3 may subsequently be given a dose of involved-site radiation therapy (ISRT) &/or additional 2 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD)
    • Deauville 4 patients may be given 2 additional cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD), together with involved-site radiation therapy (ISRT)
    • Additional 2 Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) cycles may be administered in patients with Deauville 5 scores if follow-up biopsy was negative
  • Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) or 2 cycles of dose-escalated Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone (BEACOPP) plus involved-site radiation therapy (ISRT) for patients <60 yr of age are effective treatment options for patients unresponsive or intolerant to Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) regimen
    • Studies have shown that Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) regimen exhibited high efficacy against locally extensive & advanced Hodgkin's lymphoma when given concomitantly with involved-field radiation therapy (IFRT)
  • Three cycles of Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) followed by involved-site radiation therapy (ISRT) is suggested for patients with bulky mediastinal disease or bulky disease >10 cm with B symptoms, & for patients with non-bulky disease
    • Restaging should be done after completion of Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) cycles
  • Initial treatment with 2 cycles of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone (BEACOPP), followed by Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) & involved-field radiation therapy (IFRT) may improve tumor control & progression-free survival
    • Significant outcome improvements were seen in classic Hodgkin's lymphoma (CHL) patients with unfavorable prognosis that were given 2 cycles of escalated Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone (BEACOPP)

Stage III/IV Classic Hodgkin's Lymphoma (CHL)

  • Initial treatment with 2 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) is recommended, followed by restaging with positron emission tomography (PET) scan
    • Patients with Deauville scores of 1-3 may subsequently be given a dose of involved-site radiation therapy (ISRT) &/or additional 4 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD)
    • For Deauville 4-5 patients, additional 4 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) is recommended
    • Addition of 4 cycles of escalated Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone (BEACOPP) may help improve outcome in patients with Deauville score of 4-5
    • Studies have shown that patients given Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) or Mechlorethamine, Vincristine, Procarbazine, & Prednisone (MOPP)/Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine  (ABVD) therapies presented with 45-50% progression free survival rates & 65% overall survival rates
  • Dose-escalated Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone (BEACOPP) & Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) are effective alternative regimens
    • Three cycles of Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) or 6 cycles of dose-escalated Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone (BEACOPP) are recommended treatment alternatives, followed by restaging after completion of treatment regimen
    • Involved-site radiation therapy (ISRT) may be given to positron emission tomography (PET)-positive sites of patients with Deauville score of 1-3 with bulky disease, Deauville 4 with positron emission tomography (PET)-positive sites, & for Deauville 4-5 patients with negative biopsies & bulky disease
  • Use of Mechlorethamine, Vincristine, Procarbazine, & Prednisone (MOPP) regimen has been discouraged in the past years due to increasing cases of male infertility & myelodysplasia in patients

Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL) 

  • Chemotherapy [ie Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP), Cyclophosphamide, Vincristine, Prednisone (CVP)] plus radiation therapy, with or without Rituximab is recommended for patients with stage IB/IIB & stage IA/IIA bulky disease
  • Chemotherapy [ie Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP), Cyclophosphamide, Vincristine, Prednisone (CVP)] with or without radiation therapy, with or without Rituximab is recommended for all patients with stage III-IV nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL)
  • Initial treatment with 2 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) is recommended, followed by restaging with positron emission tomography (PET) scan
    • Patients with Deauville scores of 1-3 may subsequently be given a dose of involved-site radiation therapy (ISRT) &/or additional 4 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD)
    • For Deauville 4-5 patients, additional 4 cycles of Doxorubicin, Bleomycin, Vinblastine, & Dacarbazine (ABVD) is recommended
    • Addition of 4 cycles of escalated Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone (BEACOPP) may help improve outcome in patients with Deauville score of 4-5
  • Dose-escalated Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, & Prednisone (BEACOPP) & Mechlorethamine, Doxorubicin, Vinblastine, Vincristine, Bleomycin, Etoposide, & Prednisone (Stanford V) (Stanford V) are effective alternative regimens
  • Rituximab with or without chemotherapeutic regimens has been considered in various clinical studies as an alternative treatment, since nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) cells express CD20 antigens
    • Some patients can be given Rituximab monotherapy as maintenance if proven responsive to this regimen

Refractory/Relapsed Disease

  • Confirmatory biopsy should be obtained prior to initiation of therapy
  • Positron emission tomography-computed tomography (PET-CT), fluorodeoxyglucose-positron emission tomography (FDG-PET) & gallium-60 may also be used to determine the prognosis of relapsed Hodgkin's lymphoma
  • Relapse rate for patients given radiation therapy for Hodgkin's lymphoma accounts to 30-35%, with occurrence within 3 year after completion of treatment
  • For patients who completed chemotherapy, about 10% develops disease progression or relapse within 3 month after, 15% presents with disease relapse within 12 month of complete remission, & about 15% develops late relapses after complete remission of >12 month

Treatment

  • High-dose chemotherapy with autologous stem cell transplantation (ASCT) is recommended for both refractory & relapsed classic Hodgkin's lymphoma
  • Conventional chemotherapy is recommended for patients previously treated with radiotherapy for early-stage Hodgkin's lymphoma
  • Indicated for patients who achieved initial complete remission
  • Includes radiotherapy for non-irradiated localized disease, conventional salvage chemotherapy, & high-dose chemotherapy then autologous stem cell transplantation (ASCT)
  • For patients who achieved complete remission with completed chemotherapy but later on experienced recurrence, high-dose chemotherapy plus autologous stem cell transplantation (ASCT) is recommended, with 30-65% long-term disease-free survival rates recorded
  • Salvage regimens are recommended to reduce tumor burden & mobilize stem cells prior to high-dose chemotherapy with autologous stem cell transplantation (ASCT)

Refractory Classic Hodgkin's Lymphoma (CHL) Disease

  • Second-line chemotherapeutic agents (eg Everolimus, Brentuximab vedotin) may be considered prior to initiation of high-dose chemotherapy with autologous stem cell transplantation (ASCT)
  • Involved site radiation therapy may be given if areas with relapse that have no history of irradiation
  • A Deauville score of 1-3 may prompt treatment with high-dose chemotherapeutic agents with autologous stem cell transplantation (ASCT) with or without involved site radiation therapy
  • Patients with Deauville scores of 4-5 may be given additional 2nd-line therapy
  • Re-evaluation of Deauville score should be done to assess response to 2nd-line treatment
  • Third-line agents used for relapsed/refractory classic Hodgkin's lymphoma include Bendamustine & Lenalidomide

Relapsed Classic Hodgkin's Lymphoma (CHL) Disease

  • Observation is advised for patients with negative biopsies
  • Restaging is recommended for patients with a positive biopsy
  • Second-line therapy with or without involved-site radiation therapy (ISRT) or high-dose chemotherapeutic agents with autologous stem cell transplantation (ASCT) is preferred for stage IA/IIA classic Hodgkin's lymphoma patients previously treated with chemotherapy but unresponsive
  • Second-line therapy is recommended for all other stages who were previously treated with monotherapy or combined modality therapy
  • Involved site radiation therapy (ISRT) alone may also be considered

Relapsed/Refractory Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

  • Observation is advised for patients with negative biopsies & asymptomatic patients
  • Second-line therapy includes Rituximab with or without chemotherapy or involved site radiation therapy is recommended for symptomatic patients
  • Rituximab may be given for 2 years as maintenance treatment if previously responsive to this regimen
  • Reevaluation & follow-up biopsy is recommended after treatment & if with disease progression despite all treatments
  • Patients with progressive disease should be assessed for disease transformation to diffuse large B-cell lymphoma (DLBCL) 

Brentuximab vedotin

  • A antibody-drug combination consisting of a CD30 antibody & microtubule disrupting agent
  • Indicated for Hodgkin's lymphoma patients who were unresponsive or with contraindications to autologous stem cell transplantation (ASCT) &/or 2 chemotherapeutic regimens

Regimens for Relapsed or Refractory Hodgkin's lymphoma

  • C-MOPP (Cyclophosphamide, Vincristine, Procarbazine, & Prednisone)
  • DHAP (Dexamethasone, Cisplatin, high-dose Cytarabine)
  • ESHAP (Etoposide, Methylprednisolone, high-dose Cytarabine, Cisplatin)
  • GCD (Gemcitabine, Carboplatin, Dexamethasone)
  • GVD (Gemcitabine, Vinorelbine, liposomal Doxorubicin)
  • ICE (Ifosfamide, Carboplatin, Etoposide)
  • IGEV (Ifosfamide, Gemcitabine, Vinorelbine)
  • Mini-BEAM (Carmustine, Cytarabine, Etoposide, Melphalan)
  • MINE (Etoposide, Ifosfamide, Mesna, Mitoxantrone)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, Yesterday
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
07 Oct 2017
Women who follow a low-fat dietary pattern appear to have reduced breast cancer mortality, according to data from the Earlier Women’s Health Initiative Dietary Modification trial.
Pearl Toh, 5 days ago
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.
Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.